Remodulin

Remodulin (treprostinil)

Background
Pulmonary arterial hypertension is a rare disorder of the pulmonary arteries in which the pulmonary arterial pressure rises above normal levels in the absence of left ventricular failure. This condition can progress to cause right-sided heart failure and death. Remodulin is indicated for treatment of pulmonary arterial hypertension (PAH) which is classified by WHO as Group 1. Remodulin is used to treat pulmonary arterial hypertension (PAH, high blood pressure in the lungs) to improve the exercise ability (1).

The World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)

WHO Group 1: Pulmonary Arterial Hypertension (PAH)
1.1 Idiopathic (IPAH)
1.2 Heritable PAH
   1.2.1 Germline mutations in the bone morphogenetic protein receptor type 2 (BMPR2)
   1.2.2 Activin receptor-like kinase type 1 (ALK1), endoglin (with or without hereditary hemorrhagic telangiectasia), Smad 9, caveolin-1 (CAV1), potassium channel super family K member-3 (KCNK3)
1.2.3 Unknown
1.3 Drug-and toxin-induced
1.4 Associated with:
   1.4.1 Connective tissue diseases
1.4.2 HIV infection
1.4.3 Portal hypertension
1.4.4 Congenital heart diseases
1.4.5 Schistosomiasis

1’. Pulmonary vena-occlusive disease (PVOD) and/or pulmonary capillary hemangiomatosis (PCH)
1”. Persistent pulmonary hypertension of the newborn (PPHN)

WHO Group 2: Pulmonary Hypertension Owing to Left Heart Disease
2.1 Systolic dysfunction
2.2 Diastolic dysfunction
2.3 Valvular disease
2.4 Congenital/acquired left heart inflow/outflow tract obstruction and congenital cardiomyopathies

WHO Group 3: Pulmonary Hypertension Owing to Lung Disease and/or Hypoxia
3.1 Chronic obstructive pulmonary disease
3.2 Interstitial lung disease
3.3 Other pulmonary diseases with mixed restrictive and obstructive pattern
3.4 Sleep-disordered breathing
3.5 Alveolar hypoventilation disorders
3.6 Chronic exposure to high altitude
3.7 Developmental abnormalities

WHO Group 4: Chronic Thromboembolic Pulmonary Hypertension <CTEPH>
5.1 Hematologic disorders: Chronic hemolytic anemia, myeloproliferative disorders, splenectomy
5.2 Systemic disorders: sarcoidosis, pulmonary Langerhans cell histiocytosis: lymphangioleiomyomatosis, neurofibromatosis, vasculitis
5.3 Metabolic disorders: glycogen storage disease, Gaucher’s disease, thyroid disorders
5.4 Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure on dialysis, segmental PH

The American College of Chest Physicians (ACCP) has published an updated clinical practice guideline for treating PAH. These guidelines use the New York Heart Association (NYHA) functional classification of physical activity scale to classify PAH patients in classes I-IV based
on the severity of their symptoms (3). Remodulin is indicated for patients with NYHA Functional Class II, III, and IV (1).

<table>
<thead>
<tr>
<th>Class I</th>
<th>Patients with pulmonary hypertension but without resulting limitation of physical activity. Ordinary physical activity does not cause undue dyspnea or fatigue, chest pain or near syncope.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class II</td>
<td>Patients with pulmonary hypertension resulting in slight limitation of physical activity. These patients are comfortable at rest, but ordinary physical activity causes undue dyspnea or fatigue, chest pain or near syncope.</td>
</tr>
<tr>
<td>Class III</td>
<td>Patients with pulmonary hypertension resulting in marked limitation of physical activity. These patients are comfortable at rest, but less than ordinary physical activity causes undue dyspnea or fatigue, chest pain or near syncope.</td>
</tr>
<tr>
<td>Class IV</td>
<td>Patients with pulmonary hypertension resulting in inability to perform any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnea and/or fatigue may be present at rest, and discomfort is increased by any physical activity.</td>
</tr>
</tbody>
</table>

**Regulatory Status**

FDA-approved indication: Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to diminish symptoms associated with exercise (1).

Adverse reactions reported with Remodulin in over 20% of patients in clinical trials include infusion site pain, infusion site reaction, headache, diarrhea and nausea (1).

Concomitant administration of Remodulin with diuretics, antihypertensive agents or other vasodilators may increase the risk of symptomatic hypotension. Since Remodulin inhibits platelet aggregation, there may be an increased risk of bleeding, particularly among patients receiving anticoagulants (1).

Safety and effectiveness in pediatric patients have not been established (1).

**Related policies**
Adcirca, Adempas, Flolan/Veletri, Letairis, Opsumit, Orenitram, Revatio, Tracleer, Tyvaso, Uptravi, Ventavis

**Policy**

This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.
Remodulin may be considered **medically necessary** in patients 18 years of age and older and for the treatment of pulmonary arterial hypertension, WHO Group I and if the conditions indicated below are met.

Remodulin may be considered **investigational** for patients less than 18 years of age and for all other indications.

**Prior-Approval Requirements**

**Age** 18 years of age or older

**Diagnoses**

Patient must have **ONE** of the following:

1. Pulmonary Arterial Hypertension (PAH) - **WHO Group I**
   - NYHA functional classification of physical activity – **Class II, III, or IV**

2. Transition from Epoprostenol (Flolan/Veletri) to reduce rate of clinical deterioration

**Prior – Approval Renewal Requirements**

**Age** 18 years of age or older

**Diagnoses**

Patient must have **ALL** of the following:

1. Pulmonary Arterial Hypertension (PAH) - **WHO Group I**

2. Symptoms have improved or stabilized

**Policy Guidelines**

**Pre - PA Allowance**

None

**Prior - Approval Limits**

**Duration** 2 years
**Prior – Approval Renewal Limits**

Same as above

**Rationale**

**Summary**
Pulmonary arterial hypertension is a rare disorder of the pulmonary arteries in which the pulmonary arterial pressure rises above normal levels in the absence of left ventricular failure. This condition can progress to cause heart right failure and death. Remodulin is a prostacyclin vasodilator indicated for treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in patients with NYHA class II, III, or IV. Remodulin has been shown to diminish symptoms associated with exercise. Remodulin is a potent pulmonary and systemic vasodilator formulated for subcutaneous or intravenous administration. Initiation of Remodulin must be performed in a setting with adequate personnel and equipment for physiological monitoring and emergency care (1-3).

Prior authorization is required to ensure the safe, clinically appropriate and cost effective use of Remodulin while maintaining optimal therapeutic outcomes.

**References**


**Policy History**

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>June 2012</td>
<td>Annual editorial and reference update</td>
</tr>
<tr>
<td>March 2013</td>
<td>Annual editorial and reference update</td>
</tr>
<tr>
<td>March 2014</td>
<td>Annual review and reference update</td>
</tr>
<tr>
<td>June 2016</td>
<td>Annual editorial review and reference update</td>
</tr>
<tr>
<td></td>
<td>Addition of age 18</td>
</tr>
<tr>
<td>September 2017</td>
<td>Policy number change from 5.06.05 to 5.40.17</td>
</tr>
<tr>
<td></td>
<td>Annual editorial review</td>
</tr>
</tbody>
</table>
This policy was approved by the FEP® Pharmacy and Medical Policy Committee on September 13, 2019 and is effective on October 1, 2019.